Cognitive Function & Brain Health — Peptide Research Overview

Relevant Compounds

• Semax — ACTH(4-7)PGP analog; increases BDNF, improves attention, memory consolidation, and neuroprotection. Used clinically in Russia.
• Selank — Tuftsin analog with anxiolytic and nootropic properties. Modulates GABA, serotonin, and BDNF systems without dependence.
• Dihexa — HGF/MET pathway activator shown to be 7 orders of magnitude more potent than BDNF in promoting synaptogenesis in animal models.

What the Research Shows

Semax

[Human Trial — Russia] Semax is registered as a drug in Russia for treatment of stroke, cognitive impairment, and optic nerve disorders. Clinical studies demonstrate significant increases in BDNF mRNA expression after intranasal administration. Improvements in attention span, working memory, and processing speed have been observed in clinical populations. Evidence is robust by Russian standards but limited peer-reviewed replication in Western literature exists. The compound's structure derives from ACTH(4-10) with modifications to enhance stability and CNS penetration.

In controlled trials with patients recovering from ischemic stroke, Semax accelerated neurological recovery and improved cognitive outcomes compared to standard care. Studies in healthy volunteers subjected to cognitive stress (e.g., prolonged demanding tasks) showed that Semax maintained performance levels and reduced error rates compared to placebo. Quantitative EEG studies indicate increased alpha wave activity associated with focused attention and reduced theta activity associated with mental fatigue.

The mechanism involves multiple pathways. BDNF upregulation supports synaptic plasticity, neuronal survival, and dendritic growth. Semax also modulates dopamine and serotonin metabolism in ways that enhance motivation and mood without the overstimulation of conventional stimulants. It increases expression of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF), contributing to neuroprotection and angiogenesis. Anti-inflammatory effects via reduced TNF-alpha and IL-6 may protect against neuroinflammatory cognitive decline.

Selank

[Human Trial — Russia / Preliminary] Selank is also registered in Russia for anxiety and asthenic disorders. Randomized trials show efficacy comparable to benzodiazepines for generalized anxiety without sedation or dependence. It increases enkephalin degradation resistance and modulates IL-6 production. Cognitive improvement is secondary to anxiety reduction in most trials. By reducing anxiety and improving emotional regulation, Selank indirectly supports cognitive performance, particularly in contexts where stress and worry impair function.

Studies examining Selank in asthenic syndrome (chronic fatigue with cognitive and emotional components) showed improvements in subjective cognitive symptoms including mental fog, concentration difficulties, and cognitive fatigue. Gene expression profiling reveals that Selank influences genes related to neurotransmitter synthesis, particularly GABA and serotonin pathways, as well as genes involved in stress response and inflammation.

The nootropic effects appear more subtle than Semax's direct cognitive enhancement, but Selank's value lies in creating optimal conditions for cognitive function by reducing anxiety, improving mood stability, and supporting stress resilience. The combination of Selank and Semax is commonly discussed in research contexts for individuals facing high cognitive demands with concurrent stress.

Dihexa

[Animal Study] Developed at Washington State University, Dihexa activates the HGF/MET signaling pathway to promote dendritic spine formation and synaptogenesis. In aged rats, it reversed cognitive deficits to levels seen in young animals. Oral bioavailability is reportedly high. No human trials have been completed. The compound's potency in promoting synaptogenesis is unprecedented—cited as being 7-8 orders of magnitude more potent than BDNF in in vitro assays.

In rodent models of cognitive impairment (scopolamine-induced amnesia, aging, traumatic brain injury), Dihexa administration rapidly improved performance on spatial learning tasks (Morris water maze), recognition memory tasks, and social recognition tests. Histological examination showed increased dendritic spine density, enhanced synaptic protein expression, and neurogenesis markers in the hippocampus. Effects persisted for days to weeks after treatment cessation, suggesting lasting structural changes.

The mechanism involves binding to and activating the hepatocyte growth factor (HGF) receptor c-MET, which is expressed in the brain and regulates neuronal survival, migration, and synaptic plasticity. This pathway is distinct from BDNF/TrkB signaling, offering a novel approach to cognitive enhancement. However, the absence of human data means safety, optimal dosing, and real-world efficacy remain unknown. Anecdotal reports from research chemical users describe cognitive improvements but are not reliable evidence.

How These Compounds Work

Semax operates primarily through neurotrophic factor upregulation. BDNF is essential for learning and memory, acting as a fertilizer for neurons, promoting dendritic branching, strengthening synaptic connections, and supporting long-term potentiation (the cellular basis of memory). By increasing BDNF expression, Semax enhances the brain's capacity for plasticity and adaptation. Modulation of dopamine and norepinephrine adds to its procognitive effects, improving motivation, attention, and processing efficiency.

Selank's cognitive benefits stem from its anxiolytic and mood-stabilizing properties. Anxiety and chronic stress impair prefrontal cortex function, reduce working memory capacity, and interfere with executive function. By normalizing stress neurobiology through GABAergic modulation and enkephalin stabilization, Selank removes impediments to optimal cognitive performance. Its anti-inflammatory effects may also protect against neuroinflammation-related cognitive decline.

Dihexa's HGF/MET pathway activation represents a fundamentally different approach. Rather than modulating existing circuits, it promotes structural brain changes—new dendritic spines, enhanced synaptic density, and potentially neurogenesis. This could theoretically reverse age-related or injury-related synaptic loss. The oral bioavailability and CNS penetration make it attractive compared to peptides requiring injection, though these properties require human validation.

Who Is This For?

These compounds may benefit individuals experiencing age-related cognitive decline, students or professionals seeking cognitive optimization, or those recovering from brain injury or stroke (particularly Semax, which has clinical data in stroke populations). They are not substitutes for lifestyle interventions—sleep optimization, exercise, cognitive training, stress management, and social engagement remain foundational for brain health.

Ideal candidates for Semax include those with measurable cognitive deficits or those facing sustained high cognitive demands where performance enhancement could have significant benefits. The compound's registration in Russia for stroke recovery suggests potential benefits in neurological recovery contexts, though this use outside Russia would be off-label and experimental.

Selank is better suited for individuals whose cognitive impairment is primarily stress- or anxiety-related. Those with performance anxiety, chronic worry interfering with concentration, or stress-induced cognitive symptoms may respond well. Dihexa remains entirely experimental—no human safety or efficacy data exists, making it inappropriate for use outside of properly designed clinical trials. Interest from longevity-focused or biohacking communities does not constitute evidence.

Protocol Considerations

Semax is typically administered intranasally using 0.1% or 1% solutions. The lower concentration is used for general cognitive support (2-3 drops per nostril, 1-2 times daily), while the higher concentration is used in clinical neurology settings (similar dosing). Treatment courses commonly run 10-30 days, with some users employing longer durations or cycling protocols. Effects on focus and mental clarity are often reported within the first few days, with memory and learning effects accumulating over weeks.

Selank protocols involve intranasal 0.15% drops, 2-3 drops per nostril, 2-3 times daily for 14-28 days. For cognitive benefits stemming from anxiety reduction, consistent daily dosing is recommended. Some protocols combine Selank (for anxiety) and Semax (for direct cognitive enhancement) in the same regimen, dosed at different times of day (e.g., Selank morning and afternoon, Semax in the morning before cognitively demanding work).

Dihexa, being entirely experimental, has no established human protocol. Animal research used doses that would scale to several milligrams in humans if taken orally, but this extrapolation is speculative. Without safety data, phase 1 dose-finding trials would be necessary. The high potency raises concerns about potential overstimulation of HGF/MET signaling with unknown consequences.

What to Track

Cognitive Performance: Subjective assessment of focus, memory, mental clarity, processing speed, and cognitive fatigue. Objective testing using validated tools (e.g., Montreal Cognitive Assessment, computerized cognitive batteries, working memory tests) provides quantifiable data.

Mood and Anxiety: Baseline and ongoing assessment of mood, anxiety levels, stress perception, and emotional regulation, as these significantly impact cognitive function.

Sleep Quality: Total sleep time, sleep latency, nighttime awakenings, and subjective sleep quality. Poor sleep undermines cognitive benefits of any intervention.

Functional Outcomes: Real-world cognitive performance—work productivity, learning new skills, error rates in demanding tasks, ability to multitask or maintain attention during prolonged work.

Side Effects: Headache, irritability, overstimulation, insomnia (particularly if dosed late in day), changes in appetite or libido, or nasal irritation from intranasal formulations.

Biomarkers (if accessible): BDNF levels in serum (though peripheral BDNF may not reflect brain levels), inflammatory markers (hs-CRP, IL-6), or advanced imaging if in a clinical research context.

Evidence Summary